BACKGROUND/OBJECTIVES: Adenovirus-36 (Adv-36) infection is associated with exaggerated adipogenesis in cell culture and the development of obesity in animal models and humans, but a causal relationship remains unproven. Our objective was to determine whether serological evidence of Adv-36 infection in childhood and/or adulthood is associated with adult obesity. SUBJECTS/METHODS: Paired plasma concentrations of Adv-36 antibodies were measured by a novel enzyme-linked immunosorbent assay in a subgroup (n = 449) of the Cardiovascular Risk in Young Finns Study in childhood (mean age 11.9 years) and adulthood (mean age 41.3 years). The study group included (1) individuals who had maintained normal-weight status (2) those who became obese adults from a normal-weight status in childhood and (3) those that were overweight/obese as a child and obese as an adult. RESULTS: Mean (s.d.) time between baseline and follow-up was 29.4 (3.2) years (range 21-31 years). A total of 24.4% of individuals who were normal weight throughout life were seropositive for Adv-36 during child and/or adulthood as compared with 32.3% of those who became obese adults (P = 0.11). Those who became obese in adulthood were more likely to be Adv-36 seropositive as adults compared with those who maintained normal weight (21.3% vs 11.6%, P = 0.02). This difference was mediated by a decline in Adv-36 seropositivity between child and adulthood in those maintaining normal weight. No differences were observed in body mass index across the life course, nor in waist circumference in adult life, between those who were Adv-36 seronegative or seropositive at any age. CONCLUSIONS: Individuals who gained weight across the life course were more likely to be Adv-36 seropositive in adult life than those who did not gain weight. However, analysis of change in weight status in relation to Adv-36 positivity did not support a causal role for Adv-36 in the development of obesity.
INTRODUCTION
Over one-third of adults worldwide are either overweight or obese, 1 a condition associated with significantly increased morbidity and mortality and marked reductions in life expectancy. 2 Chronic imbalances in energy intake and expenditure are known to be central to the development of obesity, but simple diet and exercise interventions generally have been ineffective, likely because of compensatory changes of intake and expenditure. 3 Additional putative determinants contributing to a heightened propensity to weight gain, and to the development of obesity-related comorbidities, have therefore been the subject of intense interest. 4 To date, these have included genetic and epigenetic susceptibility, intestinal microbial dysbiosis and disturbances in the metabolomic profile. 5 Obesity is more common in those of lower socioeconomic status. Educational and financial restraints, and their effect on lifestyle choices, are key to mediating these social gradients, but other factors more common in those of low socioeconomic status (including smoking and infection) have been suggested to contribute to the development of obesity. 6 A number of specific microbes have been suggested to promote obesity through infection, but the majority of published data relate to associations between adenovirus-36 (Adv-36) infection and obesity. 6 Over 20 years ago, SMAM-1, an avian adenovirus, was shown to produce excessive adiposity when experimentally injected into chickens. 7 Adv-36, a human adenovirus, enhances differentiation of murine preadipocytes 8 and promotes weight gain in mice, chickens and monkeys with paradoxical reductions in cholesterol and triglycerides. [9] [10] [11] Upon initial exposure, Adv-36 infects the upper respiratory epithelium, and the fiber protein and hexon protein of Adv-36 bind to receptors on the cell membrane before viral DNA is inserted into the cells. Rapid viral replication results in viremia. The Adv-36 DNA in differentiated cells expresses transcription factors and induce enzymes that may contribute to the development of obesity by a variety of mechanisms. For example, Adv-36 infection is associated with increased differentiation of adipocytes and preadipocytes in vitro, 8 along with evidence of increased glucose uptake and de novo lipogenesis, 12 and with recruitment of adipocytes from adult stem cells within adipose tissue. 13, 14 Therefore, Adv-36 appears to induce both hypertrophy and hyperplasia of fat cells.
There are 16 studies to date that show some type of association between Adv-36 and overweight/obesity, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and 3 studies that do not. [31] [32] [33] Four of the positive studies had Adv-36 assays that were not adequately described and must be interpreted with caution. [27] [28] [29] [30] Three other studies show an association of obesity with adenoviruses other than Adv-36, including Adv-5, 26 Adv-9, 34 and an elevated adenovirus titer of nonspecific nature. 35 Therefore, the causal role of Adv-36 in the development of obesity remains unclear.
There are currently no data relating to change in Adv-36 seropositivity across the life course that examine the relationship between changes in weight status over time and titers of Adv-36 in the same individuals. Almgren et al. 21 evaluated groups of different individuals over time in Sweden and found that the prevalence of Adv-36 rose from 7 to 20% from 1992 to 2005. During this time the prevalence of obesity doubled in Sweden. 21 Lin et al. 23 evaluated body weight and diabetes status over 10 years and found that individuals who were Adv-36 positive at baseline had higher adiposity and lower glucose intolerance than Adv-36-negative individuals. Finally, a recent retrospective cohort study of 500 male military recruits assessed weight change over a mean duration of 5.2 years (range 2-17 years) in relation to baseline Adv-36 positivity. 25 The presence of Adv-36 antibodies was not associated with higher body mass index (BMI; at baseline or follow-up), but Adv-36 seropositive individuals were more likely to develop a physician-assigned diagnosis of overweight/obesity over time, especially if they were lean at baseline.
The aim of this study was to assess Adv-36 positivity in paired samples taken during both childhood (when infection is most likely to occur) and adulthood in a subgroup of the Cardiovascular Risk in Young Finns Study. Our primary hypothesis was that the prevalence of Adv-36 seropositivity would be higher in those who developed obesity over time.
SUBJECTS AND METHODS Participants
The study population comprised a preselected subgroup of participants from the Cardiovascular Risk in Young Finns Study, a populationrepresentative Finnish cohort investigating the longitudinal development of cardiovascular risk factors. 36 The study has been conducted in all five Finnish university cities with medical schools and their rural surroundings. The first cross-sectional study was conducted in 1980 and altogether 4320 children and adolescents aged 3, 6, 9, 12, 15 and 18 years were randomly chosen from the population register of these areas to produce a representative sample of Finnish children. Of these individuals, 3596 (83%) participated in the original study. Since then, six follow-ups have been conducted throughout childhood, adolescence and adulthood in 1983, 1986, 2001, 2007 and 2011 . More detailed methodology has been published previously. 37 The study has institutional ethical approval, and obtained written informed consent from the study subjects, or their parents, for each of the longitudinal examinations.
For the present study, we sampled a subgroup (n = 449) of participants who had either experienced weight gain across the life course (either in child and adulthood or only in adulthood) or maintained a normal weight status throughout life. To define adiposity status, international age-and sex-specific BMI cut-points for overweight/obesity were used in children, 38 and a cut-point of 30 kg m − 2 used in adults. Group 1 had a normal weight at both first child measurement and last measurement in adulthood. Group 2 were normal weight at first measurement in childhood, and obese at last measurement in adult life. Group 3 were overweight or obese at first measurement as a child, and obese at last measurement in adulthood. We have previously used these groupings to demonstrate that overweight or obese children who grow up to be nonobese adults have diminished risk factors for type 2 diabetes and heart disease. 39 
Anthropometry measurement
Height was measured using a wall-mounted Seca stadiometer (Seca, Hamburg, Germany) to the nearest 0.5 cm, and weight was measured with a digital Seca scale to the nearest 0.1 kg. BMI was calculated as weight (kg)/ [height(m) 2 ]. Waist circumference was measured in adults beginning from the 2001 follow-up midway between the iliac crest and the lowest rib as the average of two measurements, to the nearest 0.1 cm.
Biochemical assays, blood pressure measurement and level of education In 1980, blood pressure was measured in those aged 3 years using an ultrasound device; a standard mercury sphygmomanometer was used for those aged 6-18 years. In adulthood, a random zero sphygmomanometer was used. The first and fifth Korotkoff sounds defined systolic and diastolic blood pressures and a mean of three measurements used in analyses. Venous blood samples were drawn after a 12-h fast. Standard enzymatic methods were used for serum total cholesterol, triglycerides, high-density lipoprotein cholesterol and plasma glucose. High-density lipoprotein cholesterol level was measured after dextran sulfate precipitation and low-density lipoprotein level was calculated using Friedewald formula. Serum insulin concentration was measured in one laboratory using a modification of the immunoassay method of Herbert et al. 40 in childhood (1980, 1983 and 1986 ) and by microparticle enzyme immunoassay kit (Abbott Laboratories, Chicago, IL, USA) in adulthood (2001, 2007 and 2011) . High-sensitivity C-reactive protein levels were determined by an automated analyzer using a latex turbidimetric immunoassay. Questionnaires were used to obtain data on the parent's or participant's education.
Adv-36 assays
Serum samples (taken at the same time as the child and adult measures that were used to define weight status; 1980 and 2001/2007) were stored without significant freeze-thaw cycles at − 20°C (child samples) or − 70°C (adult samples) until Adv-36 seropositivity was tested in duplicate at Obetech Obesity Research Center, LLC (Richmond, VA, USA) by authors RLA and ZP-L who were blinded to weight status data. Analysis was performed in duplicate using a previously published Adv-36 enzyme-linked immunosorbent assay (ELISA). 21 Briefly, 100 μl of coating protein (recombinant maltose binding protein-Adv-36 fiber protein fragment, Lot: 2-1-12, Obetech, LLC) was added to each well of a 96-well ELISA microplate (Perkin Elmer, Waltham, MA, USA) and incubated overnight at 4°C. After washing 10 times, wells were blocked with 2% bovine serum albumin in phosphate-buffered saline and incubated at room temperature for 1 h. After washing 10 times with deionized water, 50 μl of a mixture of competitor protein (maltose binding protein, Lot: 2-1-12, Obetech) and horseradish peroxidase-conjugated coating protein (Obetech) were added to each well. Plates were moved to a sterile tissue culture hood and 50 μl of sera was added into the wells. Plates were sealed and incubated at room temperature with continuous shaking at 750 r.p.m. for 1 h and then washed 20 times with deionized water. Then, 50 μl of TMB substrate (3,39,5,59-tetramethylbenzidine, Thermo Scientific 34028, Rockford, IL, USA) were added to each well, the plates sealed and shaken for 5 min and then incubated at room temperature for ∼ 20 min. As TMB is light sensitive, these steps were performed in a darkened room. The reactions were stopped with 100 μl of 1 N HCl and plates read at optical density (OD) 450 nm wavelength within 20 min using a microplate reader. Each plate contained one known positive human serum control and one background control (bovine serum albumin blocking buffer only). A standard curve with dilutions of positive rabbit serum of 1:20, 1:80, 1:320 and 1:1280 was included with each assay. Samples were run at least in duplicate. To be valid, the background control had to have readings below 0.06. A reading in duplicate samples from the same individual equal to or greater than the value of the 1:320 positive control serum from the standard curve was considered positive. A reading less than this cutoff value in both duplicates was negative. Equivocal readings (one above and one below cutoff) were declared by forced choice based on the average value in relation to the cutoff value. As sample OD reading varies between ELISA plates, a full standard curve with positive and negative controls was run in each plate. It was therefore not possible to group all OD readings between assays. Analysis of antibody positivity as a continuous variable did not alter our main findings (Supplementary Table 1 ). Serum neutralization assay (SNA) was not performed given constraints to resources and serum sample volumes.
Statistical analyses
All statistical analyses were performed using SAS v9.2 (Cary, NC, USA) or STATA v13.1 (College Station, TX, USA). In adulthood, we used data from the latest available follow-up. Linear regression analyses were performed for testing differences in continuous variables either unadjusted or adjusted with age and sex. The χ 2 test was used to explore group differences in dichotomous variables. Statistical significance was inferred at a two-tailed P-value of o 0.05. Life-course analysis of BMI and waist circumference according to Adv-36 antibody seropositivity in childhood and adulthood was examined using multilevel mixed modeling with maximum likelihood estimation. This approach considers correlations between repeated measures on the same individual and allows for missing data. BMI and waist circumference trajectories were compared as a function of age for four groups in the first approach: (1) negative for Adv-36 antibody in both childhood and adulthood; (2) positive for Adv-36 antibody in childhood but not adulthood; (3) negative for Adv-36 antibody in childhood but positive in adulthood; (4) positive for Adv-36 antibody in both childhood and adulthood; and two groups using the second approach: (1) negative for Adv-36 in both childhood and adulthood; and (2) positive for Adv-36 in either childhood or adulthood. All analyses were adjusted for sex and time (a categorical age variable). Subsequently, we fitted interaction terms between Adv-36 group and time that compares the trajectory of BMI or waist circumference between groups. These analyses allow the age at which any differences in BMI or waist circumference between the groups to be identified.
RESULTS

Participant characteristics
The mean (s.d.) time between baseline and follow-up was 29.4 (3.2) years and ranged from 21 to 31 years. Participant characteristics are shown in Table 1 according to groups selected for the Adv-36 assay. The participants were selected from the larger cohort matched for sex and age at baseline.
Adv-36 seropositivity according to weight change groups over the life course
Overall, approximately one quarter (n = 40; 24.4%) of individuals who were normal weight throughout life tested positive for Adv-36 during childhood and/or adulthood as compared with 32.3% (n = 53) of those who became obese as an adult (Table 1 ; P = 0.11 for comparison between these two groups). There were no significant differences between the percentage of Adv-36 seronegative individuals across the weight status groups.
When examined whether there were significant differences in Adv-36 positivity in child or adulthood between those in the participant groups, no differences were observed in childhood, but a higher proportion of group 2 (normal weight in childhood, obese in adulthood) were Adv-36 seropositive compared with group 1 (normal weight in childhood and adulthood) ( Table 1; 21.3% vs 11.6%, P = 0.02). This effect was because of a reduction in the percentage of Adv-36 seropositive individuals in the normalweight group, as opposed to an increase in percentage of seropositive individuals in those who became obese adults.
BMI life-course trajectory according to participants' Adv-36 antibody seropositivity in childhood and adulthood Using serial measurements of BMI taken at each of the seven surveys, we modeled the mean BMI at each age for individuals by Adv-36 serology group in childhood and adulthood (Figure 1a ) and Adv-36 positivity at any time point (Figure 1b ). No significant differences in BMI in relation to Adv-36 seropositivity were observed at any age, apart from a small but statistically significant increase in BMI at age 42 years in those who became Adv-36 seropositive in adult life compared with those who remained seronegative throughout (P = 0.03, Figure 1a ). BMI among participants who were Adv-36 positive in childhood or adulthood did not differ, on average, to those who were Adv-36 negative (−0.03 kg m − 2 , 95% confidence interval, − 0.71 to 0.66 kg m − 2 , P = 0.94) across the life course (Figure 1b ).
Comparison of waist circumference measures in adult life according to participants' Adv-36 seropositivity status in childhood and adulthood We also analyzed Adv-36 seropositivity in relation to differences in mean waist circumference ( Supplementary Figure 1) . Waist circumference measures were only commenced in this sample from 2001, and therefore the trajectories only examined from age 24 to 49 years. Apart from a small yet statistically significant decrease in waist circumference at age 39 years in those who were Adv-36 seropositive at both time points compared with those who remained seronegative throughout (P = 0.04, Supplementary  Figure 1A ), there were no significant differences observed. On average, waist circumference among participants who were Adv-36 seropositive in childhood or adulthood did not differ significantly with those who were Adv-36 seronegative (−1.4 cm, 95% confidence interval, − 4.5 to 1.8 cm, P = 0.39) across the life course (Supplementary Figure 1B) .
Comparison of weight status, cardiovascular risk factors and socioeconomic status by Adv-36 antibody status in childhood and adulthood
Finally, we investigated whether those who were seropositive in both child and adult life would display higher degrees of obesity and/or lower triglycerides or cholesterol levels in either childhood or adult life. We also examined fasting insulin levels (as a surrogate marker of insulin resistance), C-reactive protein (as a measure of inflammation) and years of education (as an indicator of socioeconomic status). Data are shown in Table 2 . No differences were observed for any parameter, except those who were seropositive in both child and adult life were more likely to be female than those who were seronegative or seropositive at one time point.
DISCUSSION
There are substantial cross-sectional data supporting an association between Adv-36 seropositivity and obesity, 16, 17, 19 but a causal relationship in humans remains unproven. There are no previous reports examining changes in Adv-36 seropositivity between child and adulthood with obesity. The only longitudinal data to date come from a recent adult study that found that Adv-36 seropositivity was associated with a clinical diagnosis of overweight/obesity, but not with an increase in BMI over time. 25 This is therefore the first study to examine changes in Adv-36 seropositivity from childhood to adulthood in relation to changes in weight status and adiposity. We found a greater proportion of Adv-36 seropositivity in those who were normal weight as a child but became obese by adulthood when compared with those who maintained normal-weight status throughout. However, this difference was because of a decline in the percentage of seropositive individuals in the normal-weight group, rather than an absolute increase in Adv-36 seropositivity rates in those who became obese. We did not observe any other significant differences in BMI across the life course, or in waist circumference in adulthood, in those who became seropositive for Adv-36 when compared with those who remained seronegative. The prevalence of Adv-36 seropositivity within our cohort in child and adulthood was ∼ 20%, similar to previous reports, but possibly higher than expected for the time at which the baseline samples were collected. 21 Adenovirus infections are common in children and vary considerably in severity. Most infections are mild and affect the upper and lower respiratory, and gastrointestinal tract. There are over 50 adenovirus serotypes that are divided into four species (Adv-A to D); Adv-36 belongs to the D group. Importantly, many routine clinical assays do not differentiate between species or serotypes, 41 and little is known about the specific epidemiology, peak age of incidence or clinical features of Adv-36 infection. It would seem likely that Adv-36 infection is relatively common, probably mild and occurs predominantly in childhood; it is therefore important to assess whether childhood infection predisposes to adult obesity.
The burden of many infectious diseases is greatest in preschool children, 42 before the age that our childhood serology data were obtained. If this epidemiologic pattern is true of Adv-36 infection, and seropositivity persisted, then a greater proportion of Adv-36 seropositive individuals would be predicted to either be already obese in childhood or become obese as adults. Our findings do not support this conjecture, as the prevalence of seropositivity was not increased in obese children and/or adults relative to the normal-weight group. Instead, we found that in those with normal-weight status in both child and adulthood had a decline in Adv-36 seropositivity. This implies that the Adv-36 antibodies may decline over time and therefore individuals may lose seropositivity from an early childhood infection by the time they reach adult life. This is plausible as previous data demonstrate a decline in Adv-36 antibody titer following childhood vaccination, 43 although why obese individuals positive for Adv-36 antibodies should have seemingly persistent antibodies until adulthood whereas normalweight individuals exhibit a disappearance of antibodies is unclear. It is possible that there may be genetic factors that affect the predisposition to become obese with Adv-36 infection, immune responses may be different in obese vs lean individuals and/or repeated exposure to Adv-36 may allow permanent antibody positivity or persistence of obesity. It is also possible, although untestable in the current study, that individuals who either remained obese between childhood and adulthood, or became obese as adults, were reinfected with Adv-36 between the child and adulthood sampling time points, resulting in the seropositivity rates being maintained over the life course.
In other common human viral infections, including those that remain latent in host tissues (such as herpes viruses and hepatitis B and C), and those that cause acute transient viremia (such as measles, mumps, rubella and hepatitis A), antibodies generated in childhood are readily detectable in adulthood. There are few data on the natural history of adenovirus antibodies in humans, and none in relation to Adv-36 specifically. It is reported that adenoviruses group C may persist in tonsillar tissue, 44 but (to our knowledge) there are no data on persistence of group D, to which Adv-36 belongs. Adenovirus serology is not used in clinical practice, as historically assays have had low sensitivity, individuals mount heterotypic responses or produce inadequate antibody production. 44 The clinical diagnosis is usually made by PCR, and although feasible, specific adenovirus serotypes are not usually identified. 45, 46 It is therefore not possible to conclude whether the decrease in seropositivity in lean individuals is because of declining serum antibodies, inadequate or heterotypic responses in some individuals, or possibly because of issues with the sample storage and/or ELISA performance.
Some differences in insulin levels and lipid profile were observed in those who became Adv seropositive in adulthood compared with other groups, although the significance of these findings is uncertain. A meta-analysis of metabolic parameters associated with Adv-36 seropositivity found no differences in lipid profile or plasma glucose, although insulin levels were not assessed. 47 Our data rest on the sensitivity and specificity of the ELISA assay and this has been fairly extensively tested for specificity and sensitivity by the developers (Obetech, LLC), and has been used to investigate the association between Adv-36 exposure and obesity in several important cross-sectional studies. 21, 22, 24, 25 SNA is the gold standard for viral serology, and therefore other assays must be compared with SNA. The Adv-36 SNA does not crossreact with any of the more than 50 other known human adenoviruses, and hence a positive SNA is specific for Adv-36 infection. However, SNA is time consuming, costly and requires greater sample volumes than the ELISA, therefore precluding its use in the current study. The ELISA for this study was developed using an Adv-36 fiber protein antigen. Rabbit serum from an Adv-36 vaccinated rabbit was found to be strongly positive for Adv-36 antibodies in both ELISA and SNA. This positive control serum was serially diluted and tested in the ELISA and by SNA, and the ELISA was found to be several dilutions more sensitive than the SNA. 21 Studies with a total of 530 samples of human sera were also analyzed by SNA and ELISA; the ELISA identified a seropositive rate of 34% and the SNA a positive rate of 12% 21 (and unpublished observations, Obetech, LLC). There were 29% of samples that were ELISA positive and SNA negative, and 5% of samples that were SNA positive and ELISA negative. Thus, ELISA was significantly more sensitive than the SNA, but there were a small number of known SNA-positive samples that were not picked up by the ELISA. It is possible that these sera had only Adv-36 hexon protein antibodies and no fiber protein antibodies. A small sample of 31 sera was also tested by SNA for Adv-9 and Adv-37 and by ELISA for Adv-36. 21 There was no evidence of crossreactivity with these other two group D human adenoviruses in the ELISA. This quality assurance testing does not prove that Adv-36 ELISA could not have had nonspecific reactions with other adenoviruses, particularly other group D adenoviruses, but it gives some assurance of specificity.
This is the first study to assess burden of infection with Adv-36 across the life course using a study population that is well phenotyped for measures of cardiometabolic risk, including obesity. We acknowledge a number of limitations to this study in addition to the previously discussed potential issues with the ELISA. First, we were only able to measure Adv-36 antibodies in a subset of the Cardiovascular Risk in Young Finns Study and it is possible that measurement in all participants may have yielded different results. This is unlikely as the study sample sizes were carefully chosen to be much larger than those reported in previous cross-sectional studies. [16] [17] [18] [19] Second, we chose single time points in child and adulthood (based on sampling timeframes and sample volumes available) and it is possible that repeated measures across the life course would allow more precise measures to determine the causal association between Adv-36 infection and the development of obesity. Repeated sampling would also allow further investigation of the decline in Adv-36 seropositivity and the possibility of reinfection, but was not possible because of limited availability of serum samples. Third, it is possible that storage conditions affected the ELISA performance. The serum samples used in this study were collected ∼ 26 years apart, frozen shortly after collection and not subject to repeated freeze-thaw cycles. Generally viral serology should be robust to these conditions; for example, non-human primate samples stored for 47 years in the study by Dhurandhar et al. 9 continued to be positive for Adv-36 antibodies. In addition, the studies by Almgren et al. 21 and Voss et al. 25 used samples that were ∼ 20 years old and these demonstrated Adv-36 positivity. In addition, the childhood samples were stored at − 20°C, whereas the adult samples were stored at − 70°C, reflecting standard procedures at the time the samples were collected. We have previously found similar Adv-36 ELISA performance characteristics on the samples from the same individuals immediately after blood collection and after 2 years of storage at − 20°C (RL Atkinson, unpublished data). Overall however, the possibility that prolonged storage could alter antibodies in the ELISA assay in unexpected ways, the possibility that positive Adv-36 antibody titers may change over time, and potentially other unique characteristics of the Finnish population, mean that it is difficult to have absolute confidence that our data conclusively demonstrate no causal association between Adv-36 infection and obesity. In summary, although there is a substantive body of crosssectional data that support an association between Adv-36 ELISA seropositivity and obesity, together with supportive animal mechanistic findings, conclusive data relating to causality are lacking. In this original study, assessing Adv-36 infection status in child and adult life and using unique paired samples from the same individuals taken many years apart, we found that those who gained weight were more likely to be Adv-36 positive in adult life than those who did not. However, we were unable to demonstrate any significant findings to support a causative role for Adv-36 in the development of human obesity from child to adult life. Further studies, using different longitudinal study populations and a variety of diagnostic methods, including SNA, may be warranted to explore whether Adv-36 is causally related to human obesity.
